Reza Kazemipour is the CEO and Founder of SixthRing, a performance and health optimization company leveraging diagnostics, biometrics, and AI to help individuals and organizations operate at their highest level. With over 30 years of global leadership experience across startups, venture capital, and corporate strategy, Reza brings a unique blend of execution, vision, and operational rigor to the human performance space. His background in the U.S. Navy instilled a lifelong discipline and drive, which he now channels into building scalable platforms that improve physical, cognitive, and emotional resilience, especially in high-stakes environments like healthcare, elite performance, and executive leadership.

‍

Paola Torre is a Venture Partner at Aquillius Ventures and Board Member at Life Science Angels, where she focuses on sourcing and evaluating early-stage biotech and therapeutic companies. With a background spanning both venture investing and biopharma R&D at BioMarin Pharmaceutical, Paola brings a cross-disciplinary perspective at the intersection of science, strategy, and innovation. She is passionate about advancing women’s leadership in life sciences and supporting founders developing transformative health technologies.

Abhay Kumar is a retired corporate development executive with 30+ years of experience in academia and biotech. Abhay’s focus has been on designing strategies, and business growth by acquisition or licensing of technologies and strategic partnerships. Abhay started his career at Hybritech Incorporated, the first biotech company in San Diego, where he identified novel biomarkers for diagnosis of prostate cancer. Upon acquisition of Hybritech, he continued his work at Beckman Coulter, Inc. in the field of MHC Tetramers. Abhay was part of strategy and corporate development at Invitrogen / Life Tech. Thermo Fisher for 14years, and at Beckman Coulter Life Sciences and Aldeveon LLC, both Danaheroperating companies for 4 years.

Bhargavi  is a Founding Partner at Java Capital—an operator-turned-investor focused on Deep-Tech and Climate-Tech investments. Over 18 years as an operator, advisor, and investor, she has backed 53 startups and works closely with founders through the 0→1→10 journey. Her approach blends technical rigor with business discipline, prioritizing defensible technology, capital efficiency, and clear paths to commercialization.  

At the Aquillius Sustainability Symposium, she brings a cross-border India–U.S. perspective and a passion for climate-positive innovation, looking for teams that turn breakthrough science into scalable solutions with real-world impact.

Trevor Wilkins is a career-long founder, operator, investor, and coach in the early-stage ventures space. A former Forbes 30 Under 30 Nominee, Trevor relocated to Los Angeles as an investor for Quake Capital to help establish their local office. During the pandemic, he served as the VP of Partner Engagement at ScaleHealth, a health innovation marketplace, where he connected payer, provider, and pharma organizations with agile startups. Currently, Trevor leads monthly fireside chats on health tech market trends while helping healthcare startups navigate go-to-market strategies and business operations.

Dr. HP Wang is the Founder of Ansir Innovation Center, a startup hub in San Diego, and a Venture Partner at the bio-focused incubator/studios Elmntri and Aquillius, where he helps deep-tech founders with commercialization and scaling. Having co-founded and invested in several technology startups, he has also held leadership roles at Techstars accelerators in San Diego (Qualcomm) and Taiwan. With a PhD in AI/Neuroscience from UC San Diego and the Salk Institute (published in Science) and multiple degrees in engineering and life sciences from Stanford University, where he was a Mayfield Fellow in entrepreneurial leadership, Dr. Wang bridges the gap between elite academic research and industrial execution to help interdisciplinary startups scale globally.

Kimberly Davis King has over 25 years of experience in the venture capital industry, with a strong focus on investing in and mentoring startups and high-growth companies. She is currently an Investment Partner at ImpactX Capital Partners and a lecturer at San Diego State University (SDSU). In addition, she serves as a committee member of the Alliance of Healthcare Foundation’s Impact Investment Committee, a Lead FastPath Facilitator and Coach for Founders First Capital, and a Broadway Angel investor. Kim is an advisor and board member to several early-stage and growth-stage companies, including OmniSync, The Good Face Project, New Voice Learning, Founders First Capital, Bump, and Laundris. Over the course of her career, Kim has held senior leadership roles at prominent investment firms. She was a Partner at Hercules Technology Growth Capital and a General Partner at IDG Ventures from 1997 to 2006, where she played an active role in managing and investing a $120 million captive fund. She led multiple investments in software and technology infrastructure companies, including successful IPOs such as F5 Networks (FFIV) and VA Linux (LINUX). Prior to joining IDG Ventures, she was an Associate at BankAmerica Ventures. Earlier in her career, Kim served as a Product Manager in the Multimedia Publishing Group at Microsoft and spent four years as a consultant at Andersen Consulting. She holds a B.S. in Industrial Engineering from Stanford University and an M.B.A. from Harvard Business School.

Dr. Mo Kagalwala received his Ph.D. in Biochemistry and Molecular Biology from the Southern Illinois University School of Medicine and MBA from UCSD Rady School of Management.  Dr. Kagalwala completed postdoctoral fellowships at MD Anderson Cancer Center and the Salk Institute. In 2020, he moved to Immuneering Corporation as Head/Sr. Director of Neuroscience Development where he played a pivotal role in advancing two drug pipelines, and straddled business development leading to successful pharma partnerships, including an IPO exit. Later, Dr. Kagalwala co-founded AlleoLabs, an early-stage biotech company focused on developing precision medicine for CNS diseases. His research topics mainly include Alzheimer's disease, Parkinson's disease, and other neurological disorders over the last 19years. Dr. Kagalwala enjoys mentoring next generation of entrepreneurs at the Basement and StartR programs at UCSD.